17 companies participated, for the acquisition of 37 lines of biological and biotechnological drugs.
The drugs are to care for patients with diseases such as diabetes, cancer, neurodegenerative and chronic diseases. Photo: Unsplash
It is a fact. The Social Security Fund announced that today it held a tender for biological and biotechnological drugs, including the most specialized ones, which must provide supplies until December 2023.
The process was carried out under Public Tender 05-2022, in which 17 companies participated, for the acquisition of 37 lines of medicines, one of them is the NPH, one of the many insulins used by diabetic patients and that, like the other insulins, the Social Security Fund is providing them, as explained by the executive director of Health Services and Benefits, Alex González.
This tender was made for a value of 102 million 987 thousand 791 dollars with 85 cents and with it will serve patients with diseases such as diabetes, cancer, neurodegenerative and chronic diseases.
Sending Data …
